HC Wainwright began coverage on shares of Cardiol Therapeutics (NASDAQ:CRDL - Free Report) in a report released on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock. HC Wainwright also issued estimates for Cardiol Therapeutics' Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.50) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.97 EPS.
Cardiol Therapeutics Price Performance
Shares of CRDL traded down $0.06 during trading hours on Monday, hitting $1.39. 442,287 shares of the company were exchanged, compared to its average volume of 226,191. The company has a market cap of $114.50 million, a price-to-earnings ratio of -3.55 and a beta of 1.03. Cardiol Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $3.12. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm's fifty day moving average is $1.07 and its 200 day moving average is $1.22.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, equities analysts anticipate that Cardiol Therapeutics will post -0.33 earnings per share for the current fiscal year.
Institutional Trading of Cardiol Therapeutics
Several large investors have recently bought and sold shares of the business. Jones Financial Companies Lllp acquired a new stake in Cardiol Therapeutics in the fourth quarter valued at about $25,000. Lion Street Advisors LLC raised its position in Cardiol Therapeutics by 8.5% in the first quarter. Lion Street Advisors LLC now owns 333,725 shares of the company's stock valued at $318,000 after purchasing an additional 26,059 shares during the last quarter. Cetera Investment Advisers bought a new position in Cardiol Therapeutics in the fourth quarter valued at about $56,000. Virtu Financial LLC bought a new position in Cardiol Therapeutics in the fourth quarter valued at about $61,000. Finally, Tejara Capital Ltd raised its position in Cardiol Therapeutics by 2.6% in the first quarter. Tejara Capital Ltd now owns 3,194,990 shares of the company's stock valued at $3,099,000 after purchasing an additional 79,553 shares during the last quarter. 12.49% of the stock is owned by institutional investors and hedge funds.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
